Earnings Call Insights: AbbVie Inc. (ABBV) Q1 2025 Management View CEO Rob Michael highlighted an
vzphotos/iStock Editorial via Getty Images AbbVie (NYSE:ABBV) shares traded higher in the premarket on Friday
More on AbbVie AbbVie: Thriving Beyond Humira’s Patent Cliff (Upgrade) AbbVie: Margin Expansion Potential Can
*Other Operating Data Consensus Source: Bloomberg More on AbbVie AbbVie: Thriving Beyond
AbbVie press release (NYSE:ABBV): Q1 Non-GAAP EPS of $2.46 beats by $0.06. Revenue of $13.34B
vzphotos/iStock Editorial via Getty Images AbbVie (NYSE:ABBV) is set to report its first-quarter 2025 earnings
shironagasukujira/iStock via Getty Images AbbVie (NYSE:ABBV) said it has submitted a biologics license application to
Kirk Fisher A roundup of the most recent upgrades issued by Seeking Alpha analysts. Tesla
mbbirdy Goldman Sachs made significant rating changes across its U.S. biopharma coverage on Tuesday, upgrading
Shidlovski/iStock via Getty Images AbbVie (NYSE:ABBV) said on Tuesday that the European Commission approved the